(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
Vaccine makers raise concerns over US panel's shift away from hepatitis B shots for newborns - 2Lebanese Shi’a party Amal competing, coordinating with Hezbollah, experts tell ‘Post’
- 34 injured in suburban Philadelphia nursing home explosion file negligence lawsuit
- 4‘Aid for Ukraine’ pierogi fundraiser event
- 5Fundamental Home Items Each Animal person Needs
- Instructions to Arrange Your Compensation During Medical caretaker Prospective employee meetings
- Figure out How to Recognize the Right Areas for 5G Pinnacles\
- The Force of Positive Reasoning: Day to day Attestations
- Holiday weather forecast: Where travelers can expect a wintry mix, flooding and record warmth across the U.S.
- IDF kills senior PIJ Gaza City Brigade cmdr. who infiltrated Kibbutz Nahal Oz on Oct. 7
- Brilliant and Gleaming: Excellence and Skincare Practices
- Becoming amazing at Systems administration: Individual and Expert Tips
- Relive NASA's historic Artemis 2 launch to the moon in these stunning photos
- Turkey key underlying issue as Israel, Greece, Cyprus hold summit
